Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial

Am J Hematol. 2020 Sep;95(9):E239-E242. doi: 10.1002/ajh.25867. Epub 2020 Jun 3.

¹ Cellular and Molecular Therapeutics Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
² bluebird bio, Cambridge, Massachusetts, USA.
³ Division of Hematology, Oncology & Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
⁴ Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
⁵ Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, USA.
⁶ Division of Hematology/Oncology, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA.
⁷ Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
⁸ Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
⁹ Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
¹⁰ University of California San Francisco, Benioff Children's Hospital Oakland, Oakland, California, USA.

No abstract available

Publication types